跳至主要内容
临床试验/NCT05654805
NCT05654805招募中不适用

Nutraceutical Improvement of Glucose Metabolism, NAFLD and Insulin Resistance by Oat-fiber Supplementation in Type 2 Diabetes Mellitus Patients

Charite University, Berlin, Germany2 个研究点 分布在 1 个国家目标入组 92 人开始时间: 2022年12月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
92
试验地点
2
主要终点
change in insulin resistance (Matsuda)

研究概览

简要总结

Cohort studies show an association between increased intake of insoluble (cereal) fiber and decreased risk for cardiovascular disease, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cancer, infectious and inflammatory disorders. Intervention studies, specifically addressing non-fermentable carbohydrates instead of their food sources (whole grain, pulses, legumes) are still sparse. Whole grain trials reported beneficial effects, but cannot pinpoint these benefits on fiber, as minerals, vitamins, grain protein and food matrix contribute to the metabolic results.

The antidiabetic effectiveness of cereal fiber might be explained by a) an increased secretion of incretins and other glucose-induced gastrointestinal hormones, b) an alteration of the gut microbiome, or c) a fermentation to short-chain fatty acids. Fermentable fibers (most of which are soluble) show these mechanisms, but lack strong diabetes-protective associations in cohort studies. In recent supplementation trials, insoluble, mostly non-fermentable fibers improved insulin resistance, glycemia and inflammation in patients with metabolic syndrome or prediabetes.

Between 2022-2024, we want to assess the effectiveness of insoluble, poorly fermentable cereal fiber in a shorter Intervention period in patients with high responsiveness (insulin-naïve overt type 2 diabetes mellitus with insulin resistance and NAFLD), using a fiber drinking supplement. Our triple-blinded RCT compares the metabolic effects and mechanistic outcomes of isocaloric treatments with 15 grams of oat-fiber supplement per day (vs. placebo) in 92 patients, covering an intervention period of 12 weeks.

详细描述

Cohort studies show an association between increased intake of insoluble (cereal) fiber and decreased risk for cardiovascular disease, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cancer, infectious and inflammatory disorders. Intervention studies, specifically addressing non-fermentable carbohydrates instead of their food sources (whole grain, pulses, legumes) are still sparse. Whole grain trials reported beneficial effects, but cannot pinpoint these benefits on fiber, as minerals, vitamins, grain protein and food matrix contribute to the metabolic results.

The antidiabetic effectiveness of cereal fiber might be explained by a) an increased secretion of incretins and other glucose-induced gastrointestinal hormones, b) an alteration of the gut microbiome, or c) a fermentation to short-chain fatty acids. Fermentable fibers (most of which are soluble) show these mechanisms, but lack strong diabetes-protective associations in cohort studies. In recent supplementation trials, insoluble, mostly non-fermentable fibers improved insulin resistance, glycemia and inflammation in patients with metabolic syndrome or prediabetes.

Between 2022-2024, we want to assess the effectiveness of insoluble, poorly fermentable cereal fiber in a shorter Intervention period in patients with high responsiveness (insulin-naïve overt type 2 diabetes mellitus with insulin resistance and NAFLD), using an oat fiber drinking supplement. Our triple-blinded RCT compares the metabolic effects and mechanistic outcomes of isocaloric treatments with 15 grams of oat-fiber supplement per day (vs. placebo) in 92 patients, covering an intervention period of 12 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

blinding applies to participants, study personnel and statistician

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • type 2 diabetes mellitus
  • HOMA-IR > 2.5
  • NAFLD (MR-S > 5,56 %)

排除标准

  • insulin treatment
  • diabetes type 1, 3 or 4
  • severe cardiopulmonary, renal, inflammatory, gastrointestinal, psychiatric or endocrine disorder
  • alcohol abuse or excess alcohol intake
  • recent CVD event (< 3months)
  • relevant liver disease other than NAFLD
  • current cancer diagnosis or treatment
  • allergy or incompatibility to the supplement

结局指标

主要结局

change in insulin resistance (Matsuda)

时间窗: 12 weeks

change in insulin resistance (Matsuda)

change in glucose tolerance (mixed-meal test)

时间窗: 12 weeks

change in glucose tolerance (mixed-meal test)

change in liver fat content (MRS)

时间窗: 12 weeks

change in liver fat content (MRS)

次要结局

  • change in incretins (GLP-1, GIP, PYY)(12 weeks)
  • change in FGF21(12 weeks)
  • change in fasting glucose(12 weeks)
  • change in inflammation parameters (CRP, leucocytes, IL-6, IL-1ß, IL-18, IL-10, IL-22(12 weeks)
  • change in IGF-1 and its binding proteins(12 weeks)
  • change in HbA1c(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Stefan Kabisch

Study physician

Charite University, Berlin, Germany

研究点 (2)

Loading locations...

相似试验

Nutraceutical Improvement of Glucose Metabolism,... | 临床试验